Literature DB >> 21641721

Evaluation of miltefosine for the treatment of dogs naturally infected with L. infantum (=L. chagasi) in Brazil.

H M Andrade1, V P C P Toledo, M B Pinheiro, T M P D Guimarães, N C Oliveira, J A Castro, R N Silva, A C Amorim, R M S S Brandão, M Yoko, A S Silva, K Dumont, M L Ribeiro, W Bartchewsky, S J H Monte.   

Abstract

Dogs naturally infected with Leishmania Infantum (=L. chagasi) were treated with miltefosine using different therapeutic regimens. The animals were evaluated for clinical evolution, biochemical parameters, parasite load (by real-time PCR), cytokine levels and humoral response. After treatment and during the following 24 months, there was progressive clinical improvement and complete recovery in 50% (7/14) of the treated animals. There was a decrease in the smear positivity of the bone marrow after treatment, and there was also a gradual and constant decrease in positive cultures at the end of the follow-up period. However, the PCR detection of parasite DNA remained positive. In general, all animals presented a significant increase in parasite load 6 months after treatment. The IFN-γ levels in all the groups tended to increase during follow-up period, regardless of the miltefosine dose administered. The IL-4 and IL-10 levels of the animals tended to decrease during follow-up, except after 300 days when only IL-10 increased. The serum antibodies identified antigens that ranged from 116 kDa to less than 29 kDa in the Western blot assay. Furthermore, 300 days after treatment, qualitative and quantitative differences in the antigen profiles were observed. Antigens of 97 and 46 kDa were the most intensely recognized. Higher levels of antigen-specific Leishmania IgG were detected before and 300 days after treatment in all groups. Taking together, the improvement in the clinical symptoms was not followed by parasitological clearance, suggesting that treatment with miltefosine is not recommended, especially in endemic areas like Brazil, where children are the major victims and dogs are involved in the maintenance of the parasite cycle.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21641721     DOI: 10.1016/j.vetpar.2011.05.009

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  17 in total

Review 1.  Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives.

Authors:  Fabiana Alves; Graeme Bilbe; Séverine Blesson; Vishal Goyal; Séverine Monnerat; Charles Mowbray; Gina Muthoni Ouattara; Bernard Pécoul; Suman Rijal; Joelle Rode; Alexandra Solomos; Nathalie Strub-Wourgaft; Monique Wasunna; Susan Wells; Eduard E Zijlstra; Byron Arana; Jorge Alvar
Journal:  Clin Microbiol Rev       Date:  2018-08-29       Impact factor: 26.132

2.  A new immunochemotherapy schedule for visceral leishmaniasis in a hamster model.

Authors:  Fabiana Rodrigues de Santana; Danielle Aparecida Marino da Silva; Simone Katz; Cristina Mary Orikaza; Katia Cristina Oliveira; Clara Lúcia Barbiéri
Journal:  Parasitol Res       Date:  2022-08-23       Impact factor: 2.383

3.  First study on efficacy and tolerability of a new alkylphosphocholine molecule (oleylphosphocholine-OlPC) in the treatment of canine leishmaniosis due to Leishmania infantum.

Authors:  Leticia Hernández; Rosa Gálvez; Ana Montoya; Rocio Checa; Alba Bello; Tom Bosschaerts; Herwig Jansen; Cristina Rupérez; Anny Fortin; Guadalupe Miró
Journal:  Parasitol Res       Date:  2013-11-06       Impact factor: 2.289

4.  Generation of luciferase-expressing Leishmania infantum chagasi and assessment of miltefosine efficacy in infected hamsters through bioimaging.

Authors:  Juliana Q Reimão; Jordana C Oliveira; Cristiana T Trinconi; Paulo C Cotrim; Adriano C Coelho; Silvia R B Uliana
Journal:  PLoS Negl Trop Dis       Date:  2015-02-13

Review 5.  Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease.

Authors:  Bruno Mendes Roatt; Rodrigo Dian de Oliveira Aguiar-Soares; Wendel Coura-Vital; Henrique Gama Ker; Nádia das Dores Moreira; Juliana Vitoriano-Souza; Rodolfo Cordeiro Giunchetti; Cláudia Martins Carneiro; Alexandre Barbosa Reis
Journal:  Front Immunol       Date:  2014-06-13       Impact factor: 7.561

Review 6.  Human Kinetoplastid Protozoan Infections: Where Are We Going Next?

Authors:  Alessandra Almeida Filardy; Kamila Guimarães-Pinto; Marise Pinheiro Nunes; Ketiuce Zukeram; Lara Fliess; Ludimila Pereira; Danielle Oliveira Nascimento; Luciana Conde; Alexandre Morrot
Journal:  Front Immunol       Date:  2018-07-25       Impact factor: 7.561

7.  Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation.

Authors:  Semra Palić; Patrick Bhairosing; Jos H Beijnen; Thomas P C Dorlo
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

8.  Use of a recombinant cysteine proteinase from Leishmania (Leishmania) infantum chagasi for the Immunotherapy of canine visceral Leishmaniasis.

Authors:  Josie Haydée Lima Ferreira; Lucilene Dos Santos Silva; Ieda Maria Longo-Maugéri; Simone Katz; Clara Lúcia Barbiéri
Journal:  PLoS Negl Trop Dis       Date:  2014-03-13

9.  Proteinuria reduction after treatment with miltefosine and allopurinol in dogs naturally infected with leishmaniasis.

Authors:  Daniela Proverbio; Eva Spada; Giada Bagnagatti de Giorgi; And Roberta Perego
Journal:  Vet World       Date:  2016-08-26

10.  Use of domperidone in canine visceral leishmaniasis: gaps in veterinary knowledge and epidemiological implications.

Authors:  Bruno L Travi; Guadalupe Miró
Journal:  Mem Inst Oswaldo Cruz       Date:  2018-10-18       Impact factor: 2.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.